Insider Trading February 11, 2026 01:31 AM

Weatherford Director Disposes of $230,726 in Stock; Company Posts Strong Q4 2025 Results

Charles M. Sledge sold 2,204 shares while Weatherford reported an EPS and revenue beat for the fourth quarter of 2025

By Avery Klein WFRD

A director at Weatherford International PLC sold a block of shares worth $230,726 on February 9, 2026, while the company disclosed fourth-quarter 2025 results that exceeded analyst expectations on both earnings per share and revenue. The transaction leaves the director with a substantial ongoing holding.

Weatherford Director Disposes of $230,726 in Stock; Company Posts Strong Q4 2025 Results
WFRD

Key Points

  • Director Charles M. Sledge sold 2,204 shares on February 9, 2026, totaling $230,726 at a weighted average price of $104.6852 per share.
  • After the disposition, Sledge directly owns 32,729 shares of Weatherford International PLC.
  • Weatherford reported fourth-quarter 2025 results with EPS of $1.91 versus an expected $1.47 (a 29.93% beat) and revenue of $1.29 billion versus an expected $1.26 billion - data relevant to equity investors and market participants.

Summary of transaction

Charles M. Sledge, a director of Weatherford International PLC (NASDAQ:WFRD), sold 2,204 ordinary shares of the company on February 9, 2026, for a total consideration of $230,726. The sale executed at a weighted average price of $104.6852 per share, with individual trade prices recorded between $104.67 and $104.79.

Post-transaction holdings

Following this sale, Sledge retains direct ownership of 32,729 Weatherford shares.

Quarterly financials reported

In related corporate disclosures, Weatherford released results for the fourth quarter of 2025 that outperformed market expectations. The company reported earnings per share of $1.91, surpassing the consensus estimate of $1.47 by 29.93%. Revenue for the quarter came in at $1.29 billion, slightly above the projected $1.26 billion.

Implications in brief

The combination of an insider sale and a meaningful quarterly earnings surprise is presented in company filings and the earnings release. The reported EPS and revenue figures indicate that Weatherford exceeded the market’s expectations for the quarter, and the company’s performance is described as strong within the disclosed results.

What is and is not disclosed

The filings and release provide the transaction details, the director’s remaining direct shareholdings, and the quarterly earnings and revenue metrics. The materials do not include commentary from the director explaining the reason for the stock sale, nor do they provide additional forward guidance or broader market reaction within the same disclosures.

Bottom line

The documented insider sale and the disclosed fourth-quarter results are the primary factual elements available in the public filings and company release. Sledge continues to hold a notable position after the sale, and Weatherford’s quarterly figures show an earnings and revenue beat for Q4 2025 as reported.


Note: This article is a factual restatement of the company disclosures and does not introduce further commentary beyond the information provided in those filings.

Risks

  • The filings disclose the sale but do not provide the director’s rationale for the transaction - an information gap that leaves the motivation for the trade unclear.
  • The company release and transaction notice do not include forward guidance or broader market reaction, limiting the immediate context available to investors assessing the significance of the earnings beat.
  • Available disclosures do not indicate whether additional insider transactions or institutional moves occurred around the same date, which constrains assessment of broader ownership changes.

More from Insider Trading

MapLight Therapeutics CFO Executes $1.02 Million Stock Sale Amid Clinical Milestones May 6, 2026 FIGS CFO Executes Share Sale Under Pre-Arranged Trading Plan May 6, 2026 East West Bancorp CEO Executes $3.76 Million Stock Sale Amid Recent Financial Outperformance May 6, 2026 MapLight Therapeutics General Counsel Executes Planned Stock Sale Amid Clinical Trial Milestones May 6, 2026 Travere Therapeutics Executive Executes Over $1 Million in Stock Sales May 6, 2026